(updated) aridis pharmaceuticals receives equity investment from the cystic fibrosis foundation

Los gatos, calif., dec. 12, 2022 (globe newswire) -- aridis pharmaceuticals, inc. (nasdaq: ards) , a biopharmaceutical company today announced the cystic fibrosis foundation invested $4.85 million in aridis common stock on market terms under nasdaq rules to support the ongoing development of ar-501, an inhalable broad-spectrum anti-infective currently under development for controlling debilitating chronic lung infections in cystic fibrosis (cf) patients. including this funding, the cf foundation has provided a total of $12.5 million in support. enrollment for a phase 2a study of ar-501 in cf patients was completed in november 2022. the company anticipates reporting top-line results from its phase 2a study in the first quarter of 2023.
ARDS Ratings Summary
ARDS Quant Ranking